13 Jun Drug Development & Delivery: CellProthera Announces Positive Phase 1/2b Data for ProtheraCytes Cell Therapy in Acute Myocardial Infarction
CellProthera recently announced positive results from a Phase 1/2b study of its lead ProtheraCytes in patients following a severe heart attack, positioning the stem cell therapy as a promising option to repair and regenerate heart tissue. The data was presented today by Faiez Zannad, MD, PhD, Chairman of the study’s steering committee and emeritus professor of therapeutics at the Université of Lorraine.
Drug Development & Delivery | 17 May 2024